RÉSUMÉ
We report the synthesis and biological evaluation of a series of 4'-fluoro-2'- C-substituted uridines. Triphosphates of the uridine analogues exhibited a potent inhibition of hepatitis C virus (HCV) NS5B polymerase with IC50 values as low as 27 nM. In an HCV subgenomic replicon assay, the phosphoramidate prodrugs of these uridine analogues demonstrated a very potent activity with EC50 values as low as 20 nM. A lead compound AL-335 (53) demonstrated high levels of the nucleoside triphosphate in vitro in primary human hepatocytes and Huh-7 cells as well as in dog liver following a single oral dose. Compound 53 was selected for the clinical development where it showed promising results in phase 1 and 2 trials.
Sujet(s)
Alanine/analogues et dérivés , Antiviraux/pharmacologie , Hepacivirus/effets des médicaments et des substances chimiques , Promédicaments/pharmacologie , Nucléotides uridyliques/pharmacologie , Uridine/analogues et dérivés , Alanine/synthèse chimique , Alanine/pharmacologie , Animaux , Antiviraux/synthèse chimique , Lignée cellulaire tumorale , Chiens , Hepacivirus/enzymologie , Hépatite C/traitement médicamenteux , Humains , Inhibiteurs de la synthèse d'acide nucléique/synthèse chimique , Inhibiteurs de la synthèse d'acide nucléique/pharmacologie , Phosphoramides , Promédicaments/synthèse chimique , Réplicon/effets des médicaments et des substances chimiques , Nucléotides uridyliques/synthèse chimique , Nucléotides uridyliques/métabolisme , Uridine/synthèse chimique , Uridine/pharmacologie , Protéines virales non structurales/antagonistes et inhibiteursRÉSUMÉ
INTRODUCTION: RG7128 (prodrug of PSI-6130) shows potent antiviral efficacy in patients infected with hepatitis C virus (HCV) genotypes 1, 2, or 3, with mean viral load decreases of 2.7 and 5 log(10) IU/mL, respectively, associated with 1500-mg doses twice daily after monotherapy for 2 weeks and with 1000-mg and 1500-mg doses twice daily after treatment in combination with the standard of care (SOC) for 4 weeks. RESULTS: From 32 patients treated with RG7128 monotherapy for 2 weeks, marginal viral load rebound was observed in 3 HCV genotype 1-infected patients, whereas partial response was observed in 2 genotype 1-infected patients. From 85 patients receiving RG7128 in combination with SOC, 1 HCV genotype 1-infected patient experienced a viral rebound, and 2 genotype 3-infected patients experienced a transient rebound. Five genotype 1-infected patients had an HCV load of >1000 IU/mL at the end of 4-week treatment. No viral resistance was observed, per NS5B sequencing and phenotypic studies. PSI-6130 resistance substitution S282T needs to be present at levels of ≥90% within a patient's quasispecies to confer low-level resistance. No evidence of S282T was found by population or clonal sequence analyses. CONCLUSIONS: The requirement for a predominant S282T mutant quasispecies, its low replication capacity, and the low-level resistance it confers probably contribute to the lack of RG7128 resistance observed in HCV-infected patients.
Sujet(s)
Antiviraux/usage thérapeutique , Désoxycytidine/analogues et dérivés , Hepacivirus/effets des médicaments et des substances chimiques , Hépatite C chronique/traitement médicamenteux , Interféron alpha/usage thérapeutique , Polyéthylène glycols/usage thérapeutique , Ribavirine/usage thérapeutique , Substitution d'acide aminé , Antiviraux/pharmacologie , Désoxycytidine/pharmacologie , Désoxycytidine/usage thérapeutique , Résistance virale aux médicaments/génétique , Association de médicaments , Hepacivirus/génétique , Hepacivirus/physiologie , Hépatite C chronique/virologie , Humains , Interféron alpha-2 , Nouvelle-Zélande , Protéines recombinantes , Sélection génétique , États-Unis , Charge virale , Protéines virales non structurales/génétique , Réplication virale/effets des médicaments et des substances chimiquesRÉSUMÉ
PSI-6130 (beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine) is a selective inhibitor of hepatitis C virus (HCV) replication that targets the NS5B polymerase. R7128, the prodrug of PSI-6130, has shown antiviral efficacy in patients chronically infected with HCV genotype 1a (GT-1a) and GT-1b. We observed that the compound exhibited potent in vitro activity against laboratory-optimized HCV replicons as well as against a panel of replicons containing NS5B HCV polymerases derived from GT-1a and GT-1b clinical isolates. We used the HCV replicon cell system to examine the emergence of variants with reduced sensitivity to PSI-6130. Short-term treatment of cells harboring the HCV subgenomic replicon with PSI-6130 cleared the replicon without generating resistant variants. Long-term culture of the cells under the compound selection generated the S282T substitution in a complex pattern with other amino acid substitutions in the NS5B polymerase. The presence of the coselected substitutions did not increase the moderate three- to sixfold loss of sensitivity to PSI-6130 mediated by the S282T substitution; however, their presence enhanced the replication capacity compared to the replication levels seen with the S282T substitution alone. We also observed a lack of cross-resistance between PSI-6130 and R1479 and demonstrated that long-term culture selection with PSI-6130 in replicon cells harboring preexisting mutations resistant to R1479 (S96T/N142T) results in the emergence of the S282T substitution and the reversion of S96T to wild-type serine. In conclusion, PSI-6130 presents a high barrier to resistance selection in vitro, selects for variants exhibiting only low-level resistance, and lacks cross-resistance with R1479, supporting the continued development of the prodrug R7128 as a therapeutic agent for the treatment of HCV infection.
Sujet(s)
Résistance virale aux médicaments/génétique , Variation génétique , Hepacivirus/effets des médicaments et des substances chimiques , RNA replicase/antagonistes et inhibiteurs , Réplicon/génétique , Protéines virales non structurales/antagonistes et inhibiteurs , Antiviraux/pharmacologie , Lignée cellulaire , Cytidine/analogues et dérivés , Cytidine/composition chimique , Cytidine/pharmacologie , Désoxycytidine/analogues et dérivés , Désoxycytidine/composition chimique , Désoxycytidine/pharmacologie , Hepacivirus/enzymologie , Hepacivirus/génétique , Hepacivirus/physiologie , Humains , Données de séquences moléculaires , Réplicon/effets des médicaments et des substances chimiques , Analyse de séquence d'ADN , Protéines virales non structurales/génétiqueRÉSUMÉ
OBJECTIVES: To characterize the effect of hepatitis C virus (HCV) polymerase intrinsic genetic heterogeneity on the inhibitory activity of nucleoside and non-nucleoside HCV polymerase inhibitors. METHODS: The sensitivity of genotype (GT) 1 HCV NS5B clinical isolates from treatment-naive patients to nucleoside and non-nucleoside polymerase inhibitors was assessed. The genetic diversity at the population level, as well as that of their quasispecies, was correlated with the observed reduced sensitivity to inhibitors. RESULTS: R1479 and NM107 (nucleoside analogues that have entered Phase 2 clinical trials as prodrugs R1626 and NM283, respectively) were similarly active across the tested clinical isolates. Resistance mutations to nucleoside analogues were not observed in any of the isolates. However, the activity of the non-nucleoside thumb II inhibitor NNI-1, palm I inhibitors NNI-2 and NNI-3, and palm II inhibitor HCV-796 was reduced across different isolates. This reduction in inhibitory activity for non-nucleoside inhibitors (NNIs) was, in most cases, correlated with the existence of known NNI resistance mutations in the NS5B polymerase population of the clinical isolates, as detected by population sequencing. Resistance mutations to NNIs were also observed at a low frequency within the clinical isolates' viral quasispecies that allowed for their rapid selection upon drug selective pressure. CONCLUSIONS: The higher frequency of known NNI resistance mutations or polymorphisms known to affect their antiviral potency when compared with the lack of detection of resistance mutations to the nucleoside analogues suggests a potential for primary reduced responsiveness as well as faster development of clinically significant resistance.
Sujet(s)
Antiviraux/pharmacologie , Résistance virale aux médicaments/génétique , Hepacivirus/effets des médicaments et des substances chimiques , Hepacivirus/génétique , Mutation faux-sens , Protéines virales non structurales/génétique , Séquence d'acides aminés , Substitution d'acide aminé , Cytidine/analogues et dérivés , Cytidine/pharmacologie , Hepacivirus/isolement et purification , Hépatite C chronique/virologie , Humains , Concentration inhibitrice 50 , Tests de sensibilité microbienne , Modèles moléculaires , Données de séquences moléculaires , Nucléosides pyrimidiques/pharmacologie , Analyse de séquence d'ADN , Réplication viraleRÉSUMÉ
Specific inhibitors of hepatitis C virus (HCV) replication that target the NS3/4A protease (e.g., VX-950) or the NS5B polymerase (e.g., R1479/R1626, PSI-6130/R7128, NM107/NM283, and HCV-796) have advanced into clinical development. Treatment of patients with VX-950 or HCV-796 rapidly selected for drug-resistant variants after a 14-day monotherapy treatment period. However, no viral resistance was identified after monotherapy with R1626 (prodrug of R1479) or NM283 (prodrug of NM107) after 14 days of monotherapy. Based upon the rapid selection of resistance to the protease and nonnucleoside inhibitors during clinical trials and the lack of selection of resistance to the nucleoside inhibitors, we used the replicon system to determine whether nucleoside inhibitors demonstrate a higher genetic barrier to resistance than protease and nonnucleoside inhibitors. Treatment of replicon cells with nucleoside inhibitors at 10 and 15 times the 50% effective concentration resulted in clearance of the replicon, while treatment with a nonnucleoside or protease inhibitor selected resistant colonies. In combination, the presence of a nucleoside inhibitor reduced the frequency of colonies resistant to the other classes of inhibitors. These results indicate that the HCV replicon presents a higher barrier to the selection of resistance to nucleoside inhibitors than to nonnucleoside or protease inhibitors. Furthermore, the combination of a nonnucleoside or protease inhibitor with a nucleoside polymerase inhibitor could have a clear clinical benefit through the delay of resistance emergence.
Sujet(s)
Hepacivirus/effets des médicaments et des substances chimiques , Nucléosides/pharmacologie , Inhibiteurs de protéases/pharmacologie , Réplicon/génétique , Protéines virales non structurales/antagonistes et inhibiteurs , Antiviraux/pharmacologie , Cytidine/analogues et dérivés , Cytidine/pharmacologie , Désoxycytidine/analogues et dérivés , Désoxycytidine/pharmacologie , Résistance virale aux médicaments , Hepacivirus/génétique , Hepacivirus/métabolisme , Oligopeptides/pharmacologie , Serine endopeptidases/métabolisme , Réplication virale/effets des médicaments et des substances chimiquesRÉSUMÉ
The HCV polymerase is an attractive target for the development of new and specific anti-HCV drugs. Herein, the characterization of the inhibitory effect of 2'-C-Methyl-Cytidine shows that it is a potent inhibitor of both genotype 1b and 1a HCV replicon replication, both of laboratory-optimized as well as of NS5B clinical isolates-chimera replicons. The corresponding 5'-triphosphate derivative is a potent inhibitor of native HCV replicase isolated from replicon cells and of the recombinant genotype 1b and 1a HCV polymerase-mediated RNA synthesis. Resistance to 2'-C-Methyl-Cytidine was mapped to amino acid substitution S282T in the NS5B coding region. Cross-resistance was observed to 2'-C-Methyl-Adenosine but not to interferon alpha-2a, to non-nucleoside HCV polymerase inhibitors or to R1479, a new and potent nucleoside inhibitor of NS5B polymerase. In vitro studies mapped resistance to R1479 to amino acid substitutions S96T and S96T/N142T of the NS5B polymerase. These mutations did not confer resistance to 2-C-Methyl-Cytidine, thus confirming the lack of cross-resistance between these two HCV inhibitors. These data will allow the optimization of new polymerase inhibitors and their use in combination therapy.
Sujet(s)
Antiviraux/pharmacologie , Cytidine/analogues et dérivés , Résistance virale aux médicaments , Génome viral , Hepacivirus/effets des médicaments et des substances chimiques , Hepacivirus/génétique , Antiviraux/composition chimique , Lignée cellulaire , Cytidine/composition chimique , Cytidine/pharmacologie , Hepacivirus/métabolisme , Humains , Interféron alpha/pharmacologie , Structure moléculaire , ARN viral , Réplication virale/effets des médicaments et des substances chimiquesRÉSUMÉ
Multiple nonnucleoside inhibitor binding sites have been identified within the hepatitis C virus (HCV) polymerase, including in the palm and thumb domains. After a single treatment with a thumb site inhibitor (thiophene-2-carboxylic acid NNI-1), resistant HCV replicon variants emerged that contained mutations at residues Leu419, Met423, and Ile482 in the polymerase thumb domain. Binding studies using wild-type (WT) and mutant enzymes and structure-based modeling showed that the mechanism of resistance is through the reduced binding of the inhibitor to the mutant enzymes. Combined treatment with a thumb- and a palm-binding polymerase inhibitor had a dramatic impact on the number of replicon colonies able to replicate in the presence of both inhibitors. A more exact characterization through molecular cloning showed that 97.7% of replicons contained amino acid substitutions that conferred resistance to either of the inhibitors. Of those, 65% contained simultaneously multiple amino acid substitutions that conferred resistance to both inhibitors. Double-mutant replicons Met414Leu and Met423Thr were predominantly selected, which showed reduced replication capacity compared to the WT replicon. These findings demonstrate the selection of replicon variants dually resistant to two NS5B polymerase inhibitors binding to different sites of the enzyme. Additionally, these findings provide initial insights into the in vitro mutational threshold of the HCV NS5B polymerase and the potential impact of viral fitness on the selection of multiple-resistant mutants.
Sujet(s)
Antiviraux/pharmacologie , Résistance virale aux médicaments , RNA replicase/antagonistes et inhibiteurs , Réplicon/génétique , Acides carboxyliques , Association de médicaments , Variation génétique , Hepacivirus/effets des médicaments et des substances chimiques , Hepacivirus/enzymologie , Hepacivirus/génétique , Mutation faux-sens , Sélection génétique , Thiophènes/pharmacologie , Protéines virales non structurales/antagonistes et inhibiteurs , Réplication viraleRÉSUMÉ
Hepatitis C virus (HCV) polymerase activity is essential for HCV replication. Targeted screening of nucleoside analogs identified R1479 (4'-azidocytidine) as a specific inhibitor of HCV replication in the HCV subgenomic replicon system (IC(50) = 1.28 microM) with similar potency compared with 2'-C-methylcytidine (IC(50) = 1.13 microM). R1479 showed no effect on cell viability or proliferation of HCV replicon or Huh-7 cells at concentrations up to 2 mM. HCV replicon RNA could be fully cleared from replicon cells after prolonged incubation with R1479. The corresponding 5'-triphosphate derivative (R1479-TP) is a potent inhibitor of native HCV replicase isolated from replicon cells and of recombinant HCV polymerase (NS5B)-mediated RNA synthesis activity. R1479-TP inhibited RNA synthesis as a CTP-competitive inhibitor with a K(i) of 40 nM. On an HCV RNA-derived template substrate (complementary internal ribosome entry site), R1479-TP showed similar potency of NS5B inhibition compared with 3'-dCTP. R1479-TP was incorporated into nascent RNA by HCV polymerase and reduced further elongation with similar efficiency compared with 3'-dCTP under the reaction conditions. The S282T point mutation in the coding sequence of NS5B confers resistance to inhibition by 2'-C-MeATP and other 2'-methyl-nucleotides. In contrast, the S282T mutation did not confer cross-resistance to R1479.